These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18298352)

  • 21. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
    Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
    Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metrological requirements for clinical laboratories.
    Fuentes-Arderiu X; Ferré-Masferrer M
    Clin Chem Lab Med; 2001 Jul; 39(7):660. PubMed ID: 11522117
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
    Maeda M; Hino O
    Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rationale approach toward automated clinical laboratories.
    Melville RS
    Med Instrum; 1974; 8(1):44-8. PubMed ID: 4812341
    [No Abstract]   [Full Text] [Related]  

  • 28. Equivalence of critical error calculations and process capability index Cpk.
    Chesher D; Burnett L
    Clin Chem; 1997 Jun; 43(6 Pt 1):1100-101. PubMed ID: 9191580
    [No Abstract]   [Full Text] [Related]  

  • 29. Thrombocytes as interfering factors in clinical chemistry.
    Guder WG
    J Clin Chem Clin Biochem; 1990 Jul; 28(7):445. PubMed ID: 2230661
    [No Abstract]   [Full Text] [Related]  

  • 30. Automatic analysers in clinical biochemistry.
    Rocks BF; Riley C
    Clin Phys Physiol Meas; 1986 Feb; 7(1):1-29. PubMed ID: 3514083
    [No Abstract]   [Full Text] [Related]  

  • 31. Calibration verification for Olympus and Hitachi automatic biochemistry analyzers using albumin.
    Zhou Q; Li X; Xie W; Xu J; Li S; Guo J
    Clin Lab; 2012; 58(1-2):153-9. PubMed ID: 22372358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
    Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
    Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Merits and demerits of automation system in the laboratory of clinical chemistry].
    Kawamura T; Ishimori A
    Rinsho Byori; 1988 Jul; 36(7):808-13. PubMed ID: 3236463
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum and pleural fluid biomarkers for mesothelioma.
    Creaney J; Robinson BW
    Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.
    Sonntag O; Scholer A
    Ann Clin Biochem; 2001 Jul; 38(Pt 4):376-85. PubMed ID: 11471880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adaptation of the measurement of plasma and erythrocyte glutathione peroxidase activity on Hitachi 911].
    Dever S; Vegas C; Imbert-Bismut F; Delattre J; Bonnefont-Rousselot D
    Ann Biol Clin (Paris); 1996; 54(5):199-202. PubMed ID: 8869359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
    Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of screening for malignant pleural mesothelioma.
    Pass HI; Carbone M
    Semin Thorac Cardiovasc Surg; 2009; 21(2):97-104. PubMed ID: 19822280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linearity and calibration. A clinical laboratory perspective.
    Passey RB; Maluf KC
    Arch Pathol Lab Med; 1992 Jul; 116(7):757-60. PubMed ID: 1497449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating total analytical error and its sources. Techniques to improve method evaluation.
    Krouwer JS
    Arch Pathol Lab Med; 1992 Jul; 116(7):726-31. PubMed ID: 1497445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.